Laurus Labs inks pact with MPP to manufacture molnupiravir
New Delhi: Drug firm Laurus Labs on Friday said it has inked a pact with Geneva-based MPP (Medicine Patient Pool) for manufacturing the oral COVID-19 antiviral medication molnupiravir."We are happy to sign an agreement to manufacture the oral COVID-19 antirviral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy...
New Delhi: Drug firm Laurus Labs on Friday said it has inked a pact with Geneva-based MPP (Medicine Patient Pool) for manufacturing the oral COVID-19 antiviral medication molnupiravir.
"We are happy to sign an agreement to manufacture the oral COVID-19 antirviral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission," Laurus Labs Founder and CEO Satyanarayana Chava said in a regulatory filing.
Also Read:Biophore India gets MPP licence to market molnupiravir
Molnupiravir is an orally administered ribonucleoside analog that inhibits the replication of SARS CoV2, and clinical studies have shown this drug to be active against the most common COVID-19 variants.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd